FDA Accepts for Review Supplemental New Drug Application

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FDA Accepts for Review Supplemental New Drug Application for XTANDI(R) (enzalutamide) Capsules in Metastatic Castration-Resistant Prostate Cancer With Data From Head-to-Head Studies of Enzalutamide Versus Bicalutamide

SAN FRANCISCO, CA and TOKYO, JAPAN--(Marketwired - Feb 22, 2016) - Medivation, Inc. ( NASDAQ : MDVN ) and Astellas Pharma Inc. ( TSE : 4503 ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) that they have submitted for XTANDI ® (enzalutamide) capsules in metastatic castration-resistant prostate cancer (mCRPC), which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication. Enzalutamide is approved by the FDA for the treatment of patients with mCRPC. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is October 22, 2016.

A Type-II variation to update the Summary of Product Characteristics (SmPC) has also been submitted to the European Medicines Agency.

About the TERRAIN trial The Phase 2 TERRAIN trial enrolled 375 patients in North America and Europe. The trial enrolled patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The primary endpoint of the trial was progression-free survival (PFS), defined as time from randomization to centrally confirmed radiographic progression, skeletal-related event, initiation of new anti-neoplastic therapy or death, whichever occurred first. The trial was designed to evaluate enzalutamide at a dose of 160 mg taken orally once daily versus bicalutamide at a dose of 50 mg taken once daily, the approved dose in combination with an LHRH analogue.

About the STRIVE trial The Phase 2 STRIVE trial enrolled 396 CRPC patients in the U.S. The trial randomized 257 patients with metastatic prostate cancer and 139 patients with non-metastatic prostate cancer whose disease progressed despite treatment with a LHRH analogue therapy or following surgical castration. The primary endpoint of the trial was PFS, defined as time from randomization to radiographic (bone or soft tissue) progression, prostate-specific antigen (PSA) progression (defined by Prostate Cancer Working Group 2 criteria), or death due to any cause, whichever occurs first. The trial was designed to evaluate enzalutamide at a dose of 160 mg taken once daily (n=198) versus bicalutamide at a dose of 50 mg taken once daily (n=198), the approved dose in combination with a LHRH analogue.

About XTANDI ® (enzalutamide) capsules XTANDI is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

Enzalutamide Mechanism of Action Enzalutamide is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell. In preclinical studies, enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors, and inhibit androgen receptor nuclear translocation and interaction with DNA. The clinical significance of this MOA is unknown.

Important Safety Information Contraindications XTANDI is not indicated for women and is contraindicated in women who are or may become pregnant. XTANDI can cause fetal harm when administered to a pregnant woman.

Warnings and Precautions Seizure In Study 1, conducted in patients with metastatic castration-resistant prostate cancer (CRPC) who previously received docetaxel, seizure occurred in 0.9% of XTANDI patients and 0% of placebo patients. In Study 2, conducted in patients with chemotherapy-naive metastatic CRPC, seizure occurred in 0.1% of XTANDI patients and 0.1% of placebo patients. There is no clinical trial experience re-administering XTANDI to patients who experienced a seizure, and limited safety data are available in patients with predisposing factors for seizure. Study 1 excluded the use of concomitant medications that may lower threshold; Study 2 permitted the use of these medications. Because of the risk of seizure associated with XTANDI use, patients should be advised of the risk of engaging in any activity during which sudden loss of consciousness could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during treatment.

Posterior Reversible Encephalopathy Syndrome (PRES) In post approval use, there have been reports of PRES in patients receiving XTANDI. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably MRI. Discontinue XTANDI in patients who develop PRES.

Adverse Reactions The most common adverse reactions (≥ 10%) reported from two combined clinical studies that occurred more commonly (≥ 2% over placebo) in XTANDI patients were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.

In Study 1, Grade 3 and higher adverse reactions were reported among 47% of XTANDI patients and 53% of placebo patients. Discontinuations due to adverse events were reported for 16% of XTANDI patients and 18% of placebo patients. In Study 2, Grade 3-4 adverse reactions were reported in 44% of XTANDI patients and 37% of placebo patients. Discontinuations due to adverse events were reported for 6% of both study groups.

  • Lab Abnormalities: Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1% Grade 3-4) and 6% of placebo patients (0.5% Grade 3-4). Grade 1-4 thrombocytopenia occurred in 6% of XTANDI patients (0.3% Grade 3-4) and 5% of placebo patients (0.5% Grade 3-4). Grade 1-4 elevations in ALT occurred in 10% of XTANDI patients (0.2% Grade 3-4) and 16% of placebo patients (0.2% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of XTANDI patients (0.1% Grade 3-4) and 2% of placebo patients (no Grade 3-4).
  • Infections: In Study 1, 1% of XTANDI patients compared to 0.3% of placebo patients died from infections or sepsis. In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.
  • Falls (including fall-related injuries) occurred in 9% of XTANDI patients and 4% of placebo patients. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in XTANDI patients, and included non-pathologic fractures, joint injuries, and hematomas.
  • Hypertension occurred in 11% of XTANDI patients and 4% of placebo patients. No patients experienced hypertensive crisis. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in < 1% of all patients.

Drug Interactions

Effect of Other Drugs on XTANDI Avoid strong CYP2C8 inhibitors, as they can increase the plasma exposure to XTANDI. If co-administration is necessary, reduce the dose of XTANDI. Avoid strong CYP3A4 inducers as they can decrease the plasma exposure to XTANDI. If co-administration is necessary, increase the dose of XTANDI.

Effect of XTANDI on Other Drugs Avoid CYP3A4, CYP2C9, and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.

For Full Prescribing Information for XTANDI (enzalutamide) capsules, please visit http://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf?v=1

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ‐ 800 ‐ FDA ‐ 1088.

About Medivation Inc. Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com

About Astellas Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en .

About the Medivation/Astellas Collaboration In October 2009, Medivation ( NASDAQ : MDVN ) and Astellas ( TSE : 4503 ) entered into a global agreement to jointly develop and commercialize enzalutamide. The companies are collaborating on a comprehensive development program that includes studies to develop enzalutamide across the full spectrum of advanced prostate cancer as well as advanced breast cancer. The companies jointly commercialize XTANDI in the United States and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United States.

Forward-Looking Statements This press release contains forward-looking statements regarding the supplemental New Drug Application (sNDA) for XTANDI ® (enzalutamide) capsules, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties. Actual results may differ substantially for a number of reasons, including if the data from STRIVE and/or TERRAIN are not incorporated into the prescribing information for XTANDI and other risks detailed in Medivation's filings with the Securities and Exchange Commission, or SEC, including its quarterly report on Form 10-Q for the quarter ended September 30, 2015, which was filed on November 6, 2015. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Medivation disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Astellas Contacts: For Media Tyler Marciniak Director, Communications (847) 736-7145 Email Contact For Investors So Sekine Senior Manager, Investor Relations (847) 224-9557 Email Contact Medivation Contacts: Rick Bierly Chief Financial Officer (415) 543-3470 Anne Bowdidge Senior Director, Investor Relations (650) 218-6900

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 208

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 188

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 164

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 83

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 47

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 41

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 104

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 141

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Monport MEGA: Revolutionizing Laser Engraving

Updated Category News Views 100

Monport Launches the MEGA: A Game Changer in Laser Engraving Monport Laser is excited to unveil the MEGA, the revolutionary desktop CO2 laser engraving machine that is set to redefine the standards of efficiency and safety in the industry. This innovative machine embodies a blend of advanced technology and user-friendly design, ensuring that both professionals and...

Continue Reading
Key Insights on Recent Managerial Transactions at Digitalist

Updated Category News Views 107

Recent Managerial Transactions at Digitalist Group Digitalist Group Oy has seen significant managerial activities recently, particularly involving key board members. The transactions not only reflect the movements within the company but also provide insights into the internal management strategies being implemented. Understanding the Notification Requirement The...

Continue Reading
Gold Prices Hold Steady Amid Economic Signals and Tariff Talks

Updated Category News Views 147

Gold Prices Resilient Despite Mixed Economic Factors Gold prices have shown little movement in recent Asian trading sessions. Investors are closely watching potential trade tariffs proposed by the incoming U.S. administration, while a recent dip in the dollar is providing some support for the precious metal. Throughout December, bullion prices experienced some losses due...

Continue Reading
Transforming Bitcoin Mining: HAKA MINING's Innovative Solutions

Updated Category News Views 275

Harnessing the Future of Bitcoin Mining HAKA MINING is making waves in the cryptocurrency sector with its dedicated approach to cloud mining. This UK-based company is not only providing opportunities for passive income but is also championing sustainability in energy use. This innovative cloud mining service empowers users to accumulate cryptocurrency efficiently and...

Continue Reading
RWE Unveils Solar Project, Boosting Jobs and Local Economy

Updated Category News Views 248

RWE Hits Milestone with New Solar Farm Development RWE is celebrating a significant advancement as onsite construction begins for the 98 MWac Union Ridge Solar farm, demonstrating a robust commitment to renewable energy and job creation. This project is positioned to generate jobs and foster economic opportunities in the surrounding regions. Collaborative Efforts with...

Continue Reading